<unk>  is a combination of two cystic fibrosis transmembrane conductance regulators that is FDA approved for the treatment of of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.   Common adverse reactions include dyspnea, nasopharyngitis, nausea, diarrhea, upper respiratory tract infection, fatigue, and rash.
Lumacaftor and ivacaftor
Tezacaftor / ivacaftor
Tiotropium bromide and olodaterol
Fluticasone/salmeterol
Hyquincarb
Beclomethasone dipropionate 
Fluticasone furoate
Glycopyrrolate and formoterol fumarate